To evaluate the efficacy and safety of levilimab in COVID-19 patients in the real-life clinical practice.
Material and methods
In a retrospective study, we enrolled 273 hospitalized patients (median age 62.0 years, 62.3% males) with moderately severe or severe COVID-19 who were treated with levilimab at a dose of 324 mg subcutaneously. To assess the efficacy of treatment we studied the changes in the status of patients and the clinical and laboratory parameters. The analysis of the safety included the frequency and profile of drug-related adverse reactions.
Moderately severe COVID-19 was diagnosed in 56.4% of patients and severe disease in 43.2% of patients. Most patients (76.6%) presented with bilateral pneumonia involving 25% up to 75% of lung tissue. 89% of patients had concomitant chronic diseases. At the end of follow-up, 92.7% (253/273) of patients were discharged from the hospital, including 9 (3.3%) patients who were admitted to the intensive care unit (ICU). 6.2% of patients (17/273) died, including 9 (3.3%) who were transferred to the ICU. 3 (1.1%) patients were lost from follow-up due to transfer to another hospital for organizational reasons.
Levilimab as a pathogenetic therapy for the complicated course of COVID-19 demonstrates a good clinical effect with a high proportion of discharged patients and favorable safety profile. Timely subcutaneous administration of levilimab in patients with moderate to severe COVID-19 provides the best clinical outcomes.
Levilimab, IL-6 receptor inhibitor, new coronavirus infection, COVID-19